Mineralys Therapeutics presented detailed results from its pivotal Phase 3 Launch-HTN trial at the 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025) on May 24, 2025. The trial, which enrolled over 1,000 participants, evaluated lorundrostat in patients with uncontrolled or resistant hypertension.
The data showed that lorundrostat 50 mg once daily achieved a 16.9 mmHg reduction in automatized office systolic blood pressure at Week 6 (-9.1 mmHg placebo adjusted; p < 0.0001). This reduction was sustained, reaching 19.0 mmHg at Week 12 (-11.7 mmHg placebo adjusted; p < 0.0001).
Lorundrostat demonstrated a favorable safety and tolerability profile, with anticipated on-target effects on serum electrolytes being modest and reversible. These findings reinforce lorundrostat's potential as an effective and well-tolerated treatment option for a broad population of hypertension patients in a real-world setting.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.